GlassScriptPhysician profile
Byol Shin
NPI 1669680401
$11,974.59
in general payments reported to CMS, 2019-2025
40 companies · $2,522 in 2025
The $2,522 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $1,753 · 2021: $1,660 · 2022: $1,563 · 2023: $1,937 · 2024: $1,844 · 2025: $2,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,030 · Education: $232 · Consulting Fee: $41.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,030.07 |
| Education | $231.70 |
| Consulting Fee | $41.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,523.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,505.40 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Optinose US, INC. | $1,091.18 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,041.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $965.60 | 2022-2024 | Rinvoq, Ubrelvy |
| Amgen INC. | $850.47 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $719.28 | 2019-2025 | Dupixent |
| Csl Behring | $505.21 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $305.12 | 2019-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $301.85 | 2019-2025 | |
| Mylan Specialty L.P. | $299.92 | 2020-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $288.78 | 2021-2025 | Cuvitru |
| Pfizer INC. | $258.93 | 2020-2025 | |
| Ars Pharmaceuticals Operations, INC. | $257.45 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $214.91 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byol Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.